Skip to main content
LITS
NASDAQ Life Sciences

Lite Strategy Retires 13% of Its Shares, Lifting Litecoin Backing Per Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.951
Mkt Cap
$32.368M
52W Low
$0.689
52W High
$6
52W Position info
38% above low
Off High info
84% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LITS sits 38% above its 52-week low of $0.689 on light trading volume (0.2× avg).

Summary

Lite Strategy repurchased 13% of its outstanding shares since December 2025, deploying $5.4 million from treasury operations to buy back stock at a discount to net asset value, increasing Litecoin per share.


Key Events · Financing and Capital Events · LITS

  • 13% Share Repurchase Completed

    Since December 2025, approximately 4.9 million shares—13% of the outstanding—have been repurchased at an average price of $1.11 per share, deploying $5.4 million.

  • Funded Without Debt

    The buyback was funded entirely through active treasury operations—Litecoin sales and covered call premiums—with no debt incurred, preserving a debt-free balance sheet.

  • Litecoin Backing Per Share Increased

    As of July 17, 2026, the company holds 819,070 LTC against 31,882,648 shares outstanding, increasing LTC per share as shares were repurchased below net asset value.

  • Preliminary Year-End Financials

    Preliminary FY2026 cash of $5.7 million and total liabilities of $1.1 million, subject to final audit adjustments.


Analysis · LITS · Life Sciences

Since December 2025, Lite Strategy has repurchased 4.9 million shares—13% of its outstanding—at an average price of $1.11 per share, for a total outlay of $5.4 million. The entire program was funded through treasury operations, specifically Litecoin sales and covered call premiums, without taking on any debt. Executed while the stock traded at a steep discount to net asset value, the buyback materially increases the Litecoin backing per remaining share and signals management's conviction that the shares are undervalued. The company also disclosed preliminary year-end cash of $5.7 million and only $1.1 million in liabilities, underscoring a debt-free balance sheet.

At the time of this filing, LITS was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.4M. The 52-week trading range was $0.69 to $6.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LITS - Latest Insights

LITS
May 13, 2026, 8:41 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $0.950 info
Change: -$0.280 (-23%) info
Market Cap: $32.368M info
LITS
May 13, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.950 info
Change: -$0.280 (-23%) info
Market Cap: $32.368M info
LITS
May 13, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.23
Real-time Price: $0.950 info
Change: -$0.280 (-23%) info
Market Cap: $32.368M info
LITS
Feb 17, 2026, 8:45 AM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $0.950 info
Change: -$0.170 (-15%) info
Market Cap: $32.368M info
LITS
Feb 12, 2026, 5:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.950 info
Change: -$0.080 (-8%) info
Market Cap: $32.368M info